Reviewing Interpace Biosciences (OTCMKTS:IDXG) & InspireMD (NYSE:NSPR)

Interpace Biosciences (OTCMKTS:IDXG) and InspireMD (NYSE:NSPR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

Profitability

This table compares Interpace Biosciences and InspireMD’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Interpace Biosciences	65.25%	219.07%	105.05%
InspireMD	-413.96%	-69.42%	-57.68%

Volatility and Risk

Interpace Biosciences has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500. Comparatively, InspireMD has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500.

Insider and Institutional Ownership

5.7% of Interpace Biosciences shares are held by institutional investors. Comparatively, 44.8% of InspireMD shares are held by institutional investors. 5.5% of Interpace Biosciences shares are held by insiders. Comparatively, 34.1% of InspireMD shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Interpace Biosciences and InspireMD”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Interpace Biosciences	$38.73 million	0.21	$24.58 million	($0.05)	-36.40
InspireMD	$10.85 million	4.32	-$19.92 million	($0.73)	-1.37

Interpace Biosciences has higher revenue and earnings than InspireMD. Interpace Biosciences is trading at a lower price-to-earnings ratio than InspireMD, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Interpace Biosciences and InspireMD, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Interpace Biosciences	0	0	0	0	0.00
InspireMD	0	0	3	0	3.00

InspireMD has a consensus price target of $4.50, indicating a potential upside of 350.00%. Given InspireMD’s stronger consensus rating and higher probable upside, analysts plainly believe InspireMD is more favorable than Interpace Biosciences.

Summary

InspireMD beats Interpace Biosciences on 8 of the 14 factors compared between the two stocks.

About Interpace Biosciences

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

About InspireMD

InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.